Selective activation of PPARγ inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator

Surgery

Volumn 134, Issue 2, 2003, Pages 206-212

  Farrow, Buckminster ^b   O'Connor, Kathleen L ^b   Hashimoto, Koji ^b   Iwamura, Takeshi ^b   Evers, B Mark ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

15D PGJ2; 15DEOXY DELTA12,14 PROSTAGLANDIN J2; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TISSUE PLASMINOGEN ACTIVATOR; TROGLITAZONE; UNCLASSIFIED DRUG; 15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL RECEPTOR; CHROMAN DERIVATIVE; DRUG DERIVATIVE; INTEGRIN; MATRIX METALLOPROTEINASE; PROSTAGLANDIN D2; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PREVENTION; CELL STRAIN ASPC 1; CELL STRAIN SUIT 2; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CULTURE MEDIUM; DNA MICROARRAY; DRUG MECHANISM; GENE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NORTHERN BLOTTING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBONUCLEASE PROTECTION ASSAY; WESTERN BLOTTING; CELL CULTURE; DRUG ANTAGONISM; METABOLISM; PANCREAS TUMOR; PATHOLOGY;

CHROMANS; HUMANS; INTEGRINS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROSTAGLANDIN D2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0042829213     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2003.221     Document Type: Article

References (25)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: state-of-the-art care. CA Cancer J Clin 2000;50:241-68.
3. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective single-institution experience. Ann Surg 1997;225:621-36.
4. Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999;18:4554-63.
5. Yang X, Staren ED, Howard JM, Iwamura T, Bartsch JE, Appert HE. Invasiveness and MMP expression in pancreatic carcinoma. J Surg Res 2001;98:33-9.
6. Paciucci R, Tora M, Diaz VM, Real FX. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene 1998;16:625-33.
7. Mercurio AM, Bachelder RE, Rabinovitz I, O'Connor KL, Tani T, Shaw LM. The metastatic odyssey: the integrin connection. Surg Oncol Clin N Am 2001;10:313-28, viii-ix.
8. Kliewer SA, Willson TM. The nuclear receptor PPARgammaCbigger than fat. Curr Opin Genet Dev 1998;8:576-81.
9. Hashimoto K, Ethridge RT, Evers BM. Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. Int J Gastrointest Cancer 2002;32:7-22.
10. Elnemr A, Ohta T, Iwata K, Ninomia I, Fushida S, Nishimura G, et al. PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 2000;17:1157-64.
11. Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 2002;277:36602-10.
12. Ehlers RA, 2nd, Bonnor RM, Wang X, Hellmich MR, Evers BM. Signal transduction mechanisms in neurotensin-mediated cellular regulation. Surgery 1998;124:239-46; discussion 46-7.
13. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 2000;60:5558-64.
14. Abe A, Kiriyama Y, Hirano M, Miura T, Kamiya H, Harashima H, et al. Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol 2002;436:7-13.
15. Farrow B, Mark Evers B. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 2003;301:50-3.
16. Elsmer E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
17. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998;4:1046-52.
18. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A 2000;97:10990-5.
19. Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 2002;941:1-10.
20. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998;284:751-9.
21. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18 Suppl 2:S23-9.
22. Diaz VM, Planaguma J, Thomson TM, Reventos J, Paciucci R. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology 2002;122:806-19.
23. Gan X, Wong B, Wright SD, Cai TQ. Production of matrix metalloproteinase-9 in CaCO2 cells in response to inflammatory stimuli. J Interferon Cytokine Res 2001;21:93-8.
24. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001;19:1118-27.
25. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993;74:185-5.